Sage Journals: Discover world-class research

Abstract

Background:

Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin (CD62L) have been proposed as additional risk stratification parameters.

Objective:

This study aimed at verifying and integrating both parameters into one algorithm for risk stratification.

Methods:

Multicentric, international cohorts of natalizumab-treated MS patients were assessed for JCV index (1921 control patients and nine pre-PML patients) and CD62L (1410 control patients and 17 pre-PML patients).

Results:

CD62L values correlate with JCV serostatus, as well as JCV index values. Low CD62L in natalizumab-treated patients was confirmed and validated as a biomarker for PML risk with the risk factor “CD62L low” increasing a patient’s relative risk 55-fold (p < 0.0001). Validation efforts established 86% sensitivity/91% specificity for CD62L and 100% sensitivity/59% specificity for JCV index as predictors of PML. Using both parameters identified 1.9% of natalizumab-treated patients in the reference center as the risk group.

Conclusions:

Both JCV index and CD62L have merit for risk stratification and share a potential biological relationship with implications for general PML etiology. A risk algorithm incorporating both biomarkers could strongly reduce PML incidence.

Keywords

Natalizumab PML L-selectin CD62L JCV index risk stratification

Get full access to this article

View all access options for this article.

References

Polman

O’Connor

Havrdova

. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

Miller

Khan

Sheremata

. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15–23.

Tan

Koralnik

. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis. Lancet Neurol 2010; 9: 425–437.

Biogen. Biogen Idec Medical information, https://medinfo.biogenidec.com/ (2015, accessed 3 June 2015).

Calabrese

Molloy

Berger

. Sorting out the risks in progressive multifocal leukoencephalopathy. Nat Rev Rheumatol 2015; 11: 119–123.

Bloomgren

Richman

Hotermans

. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–1880.

Cutter

Stüve

. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Mult Scler 2014; 20: 1304–1305.

Kalincik

Horakova

Spelman

. Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis. Ann Neurol 2015; 77: 425–435.

Capobianco

di Sapio

Malentacchi

. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: A comparative analysis of different approaches during the first year of natalizumab discontinuation. Eur J Neurol 2015; 22: 585–587.

10.

Plavina

Subramanyam

Bloomgren

. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76: 802–812.

11.

Schwab

Schneider-Hohendorf

Posevitz

. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013; 81: 865–871.

12.

Major

Douek

. Risk factors for rare diseases can be risky to define: PML and natalizumab. Neurology 2013; 81: 858–859.

13.

Schneider-Hohendorf

Philipp

Husstedt

. Specific loss of cellular L-selectin on CD4(+) T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection. AIDS 2014; 28: 793–795.

14.

Lee

Plavina

Castro

. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 2013; 57: 141–146.

15.

Brady

HJM

. Apoptosis methods and protocols. Totowa, NJ: Humana, 2004.

16.

Chrest

Buchholz

Kim

. Identification and quantitation of apoptotic cells following anti-CD3 activation of murine G0 T cells. Cytometry 1993; 14: 883–890.

17.

Kuesters

. Anti-JC virus (JCV) antibody index differentiates risk of PML in natalizumab-treated MS patients with no prior immunosuppressant use: An updated analysis. Neurology 2015; 84: AAN Poster P4 031.

18.

Meira

Sievers

Hoffmann

. MiR-126: A novel route for natalizumab action? Mult Scler 2014; 20: 1363–1370.

19.

Villar

Costa-Frossard

Masterman

. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann Neurol 2015; 77: 447–457.

20.

Basnyat

Hagman

Kolasa

. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing–remitting MS patients. Mult Scler Relat Disord 2015; 4: 334–338.

21.

Bohl

Brennan

Ryschkewitsch

. BK virus antibody titers and intensity of infections after renal transplantation. J Clin Virol 2008; 43: 184–189.

22.

Pastrana

Brennan

Cuburu

. Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients. PLoS Pathog 2012; 8: e1002650.

23.

Pastrana

Wieland

Silling

. Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer. Med Microbiol Immunol 2012; 201: 17–23.

24.

Lieberman

. CD62L (L-selectin) is not a reliable biomarker for predicting risk of PML in natalizumab-treated MS patients. Neurology 2015; 84: AAN Poster P4 0.39.

25.

Spadaro

Caldano

Marnetto

. Natalizumab treatment reduces L-selectin (CD62L) in CD4(+) T cells. J Neuroinflammation 2015; 12: 146.

26.

Gorelik

Lerner

Bixler

. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol 2010; 68: 295–303.

27.

Jackson

Drevets

Dong

. Levels of L-selectin (CD62L) on human leukocytes in disseminated cryptococcosis with and without associated HIV-1 infection. J Infect Dis 2005; 191: 1361–1367.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.22 MB

PML risk stratification using anti-JCV antibody index and L-selectin